ABSI Reports Positive Phase 1 Data
Absci announces positive interim phase 1 data from the HEADLINE trial of ABS-201, a novel antibody targeting the prolactin receptor
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.